Powered by MOMENTUM MEDIA
Baker & McKenzie and Clayton Utz advise on the sale of Australian-based iNova Pharmaceuticals to Canada-based Valeant Pharmaceuticals.
Firms: Baker & McKenzie (Valeant Pharmaceuticals); Clayton Utz (Ironbridge and Archer Capital)
Area: M&A
Value: $625 million upfront and up to an additional $75 million in potential milestones
Key players: The Bakers team was led by Sydney-based partner David Egan and associate Michael Dearden
We're evolving — and so should your insights. Heads up — Lawyers Weekly is going premium from 1 May for just $5 a month. Stay informed without missing a beat. More information coming soon.